Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Medicine, Oncology, Pharmacology +17

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006 · 2.2K citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Lysosome-targeting chimaeras for degradation of extracellular proteins

Steven M. Banik, Kayvon Pedram, Simon Wisnovsky et al. · Nature · 2020 · 1.1K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Ki Y. Chung, Jinru Shia, Nancy E. Kemeny et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +15